Guidelines for TCM Intervention After Conventional Western Medicine Treatment for Stage Ⅰ-Ⅲ Colorectal Cancer

HE Bin; LIU Jianping; SUN Hong; YANG Yufei; LI Minzhe; LI Pingping; LIU Likun; SHU Peng; SUN Zhigang; WANG Wei; ZENG Puhua; ZHANG Hongliang

doi:10.13422/j.cnki.syfjx.20230548

您当前的位置：

首页 >

文章列表页 >

Guidelines for TCM Intervention After Conventional Western Medicine Treatment for Stage Ⅰ-Ⅲ Colorectal Cancer

更新时间：2023-10-13

- Guidelines for TCM Intervention After Conventional Western Medicine Treatment for Stage Ⅰ-Ⅲ Colorectal Cancer
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 29, Issue 21, Pages: 1-9(2023)
- 作者机构：
  
  1.中国中医科学院西苑医院，北京100091
  2.北京中医药大学，北京100105
  3.北京大学肿瘤医院，北京100142
  4.首都医科大学附属北京朝阳医院，北京100020
  5.山西省中医院，太原030012
  6.江苏省中医院，南京210004
  7.郑州市中医院，郑州450006
  8.重庆大学附属肿瘤医院，重庆400030
  9.湖南省中医药研究院附属医院，长沙410006
  10.新疆维吾尔自治区中医医院，乌鲁木齐830099
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20230548
  CLC： R22;R24;R73;R28
- Published：05 November 2023，
  
  Published Online：16 February 2023，
  
  Received：07 October 2022，
- 稿件说明：
扫描看全文
何斌,刘建平,孙红等.Ⅰ~Ⅲ期结直肠癌西医常规治疗后中医干预指南[J].中国实验方剂学杂志,2023,29(21):1-9.

HE Bin,LIU Jianping,SUN Hong,et al.Guidelines for TCM Intervention After Conventional Western Medicine Treatment for Stage Ⅰ-Ⅲ Colorectal Cancer[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(21):1-9.
何斌,刘建平,孙红等.Ⅰ~Ⅲ期结直肠癌西医常规治疗后中医干预指南[J].中国实验方剂学杂志,2023,29(21):1-9. DOI： 10.13422/j.cnki.syfjx.20230548.

HE Bin,LIU Jianping,SUN Hong,et al.Guidelines for TCM Intervention After Conventional Western Medicine Treatment for Stage Ⅰ-Ⅲ Colorectal Cancer[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(21):1-9. DOI： 10.13422/j.cnki.syfjx.20230548.

摘要

结直肠癌是常见的高发病率恶性肿瘤之一，我国近几十年来生活方式、饮食结构和环境的改变与结直肠癌发病率的升高有关。已有大量研究表明，中医药可作为结直肠癌西医常规治疗后的补充和替代治疗。中医医师在Ⅰ~Ⅲ期结直肠癌患者的治疗中积累了大量临床经验，且证明中医药具有独特疗效，但尚缺乏规范和指导中医诊疗的相关临床实践指南。基于此，笔者根据《世界卫生组织指南制定手册》的指南制定流程及《基于证据体的中医药临床证据分级标准》，在法律法规和技术指导文件的框架下，结合近年来国内外相关的临床研究证据进行证据分级和意见推荐，经专家共识研制形成《Ⅰ~Ⅲ期结直肠癌西医常规治疗后中医干预指南》。该指南介绍了结直肠癌中医干预的病因病机、辨证论治等内容，可为从事结直肠癌防治的中医临床医师、中西医结合临床医师提供指导性意见。

Abstract

Colorectal cancer is one of the common malignant tumors with high morbidity， and changes in lifestyle， dietary structure and environment in China in recent decades have been associated with an increase in the incidence of colorectal cancer. A large number of studies have shown that traditional Chinese medicine（TCM） can be used as a complementary and alternative treatment for colorectal cancer after conventional western medicine treatment. TCM physicians have accumulated a lot of clinical experience in the treatment of patients with stage Ⅰ-Ⅲ colorectal cancer， and have proved that TCM has unique efficacy， but there is still a lack of relevant clinical practice guidelines to standardize and guide the diagnosis and treatment of TCM. Based on this， according to the guideline development process of the

World Health Organization Handbook for Guideline Development

and the

Clinical Evidence Grading Criteria on TCM Based on Evidence Body

， under the framework of relevant laws， regulations and technical guidance documents， combined with the evidence of relevant domestic and foreign clinical research in recent years for evidence grading and opinion recommendation， and then the

Guidelines for TCM Intervention After Conventional Western Medicine Treatment for Stage

Ⅰ-Ⅲ

Colorectal Cancer

were developed by expert consensus. This guideline introduces the etiology， pathogenesis， syndrome differentiation and treatment of TCM intervention for colorectal cancer， which can provide guiding opinions for TCM clinicians and clinicians of integrated traditional Chinese and western medicine engaged in the prevention and treatment of colorectal cancer.

关键词

Ⅰ~Ⅲ期结直肠癌中医药（TCM）指南方剂证候中西医结合Meta分析

Keywords

stage Ⅰ-Ⅲ colorectal cancertraditional Chinese medicine（TCM）guidelinesformulassyndromeintegrated traditional Chinese and western medicineMeta analysis

references

SUNG H，FERLAY J，SIEGEL R L，et al.Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2021，71（3）：209-249.

ZHENG R S，ZHANG S W，ZENG H M，et al.Cancer incidence and mortality in China，2016［J］.J Natl Cancer Cent，2022，2（1）：1-9.

SIEGEL R L，TORRE L A，SOERJOMATARAM I，et al.Global patterns and trends in colorectal cancer incidence in young adults［J］.Gut，2019，68（12）：2179-2185.

QADESI S M，DICKMAN P W，DE-WILT J H，et al.Conditional survival and cure of patients with colon or rectal cancer：A population-based study［J］.J Natl Compr Canc Netw，2020，18（9）：1230-1237.

张卫刚，张言言，张宪文，等.不同分期结直肠癌患者的预后分析：一项基于SEER数据库的回顾性研究［J］.中华结直肠疾病电子杂志，2017，6（1）：21-27.

XU Y，MAO J J，SUN L Y，et al.Association between use of traditional Chinese medicine herbal therapy and survival outcomes in patients with stage Ⅱ and Ⅲ colorectal cancer：A multicenter prospective cohort study［J］.J Natl Cancer Inst Monogr，2017，doi：10.1093/jncimonographs/lgx015http://dx.doi.org/10.1093/jncimonographs/lgx015.

张良登，姜敏，潘国凤.中医药治疗结直肠癌队列研究的文献质量评价［J］.中医肿瘤学杂志，2021，3（4）：77-81.

VOGELAAR I，VAN BALLEGOOIJEN M，SCHRAG D，et al.How much can current interventions reduce colorectal cancer mortality in the US？Mortality projections for scenarios of risk factor modification，screening，and treatment［J］.Cancer，2006，107（7）：1624-1633.

VARGHESE C，SHIN H R.Strengthening cancer control in China［J］.Lancet Oncol，2014，15（5）：484-485.

杨克虎.世界卫生组织指南制定手册［M］.兰州：兰州大学出版社，2013.

陈薇，方赛男，刘建平.基于证据体的中医药临床证据分级标准建议［J］.中国中西医结合杂志，2019，39（3）：358-364.

陈薇，陈可冀，刘建平.中医药真实世界研究证据的构成及分级标准建议［J］.中国中西医结合杂志，2021，41（5）：608-611.

国家中医药管理局医政司.24个专业105个病种中医诊疗方案［M］.北京：国家中医药管理局医政司，2011：330-335.

赵娜，裴晓华，徐钰莹，等.杨宇飞教授运用健脾补肾序贯法防治结直肠癌化疗副反应的经验［J］.世界科学技术—中医药现代化，2020，22（10）：3645-3649.

李灿东，吴承玉.中医诊断学［M］.3版.北京：中国中医药出版社，2012.

王永炎，张天，李迪臣，等.临床中医内科学［M］.北京：北京出版社，1994.

王笑民.实用中西医结合肿瘤内科学［M］.北京：中国中医药出版社，2014.

李国彰.生理学［M］.北京：科学出版社，2008.

张伯礼，吴勉华，林子强.中医内科学［M］.北京：中国中医药出版社，2019.

闫韶花，许云，孙凌云，等.“两阶段三部曲”在结直肠癌辅助化疗期的应用［J］.世界科学技术—中医药现代化，2020，22（10）：3640-3644.

杨宇飞.基于“损者益之”的序贯健脾补肾法协同化疗方案刍议［J］.中医杂志，2021，62（2）：125-129.

赵诚和.中医经方干预Ⅱ、Ⅲ期结直肠癌预后及中医证型动态演变规律研究［D］.北京：北京中医药大学，2017.

刘繁荣，张友杰.加味八珍汤联合XELOX方案治疗结直肠癌术后的临床疗效［J］.现代中医药，2020，40（2）：94-97.

YANG Y F，GE J Z，WU Y，et al.Cohort study on the effect of a combined treatment of traditional Chinese medicine and Western medicine on the relapse and metastasis of 222 patients with stage Ⅱ and Ⅲ colorectal cancer after radical operation［J］.Chin J Integr Med，2008，14（4）：251-256.

杨宇飞，许云，吴煜，等.祛邪胶囊减少大肠癌术后复发转移的临床随机双盲对照研究［J］.中国中西医结合杂志，2007，27（10）：879-882.

袁嘉林.扶正健脾法对大肠癌术后化疗后患者生活质量的影响［D］.广州：广州中医药大学，2016.

郑佳彬，王应天，关靓，等.复方斑蝥胶囊预防Ⅲ期结直肠癌患者术后复发转移的多中心临床研究［J］.中国中西医结合外科杂志，2020，26（1）：37-41.

关佳慧，杨宇飞，许云，等.中西医结合治疗减少Ⅱ~Ⅲ期结肠直肠癌根治术后复发转移222例队列研究的再随访［J］.癌症进展，2010，8（2）：193-195.

秦文钰.中医药干预下改善Ⅱ、Ⅲ期结直肠癌术后预后的定量与定性研究［D］.北京：中国中医科学院，2020.

张彤，刘建平，许云，等.转移性结直肠癌中医诊疗指南［J］.中国实验方剂学杂志，2023，29（21）：24-31.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Guidelines for Psychological Rehabilitation Intervention Combined Integrated Traditional Chinese and Western Medicine After Radical Surgery for Early and Middle Stage Colorectal Cancer

Meta-analysis of Integrated Traditional Chinese and Western Medicine in Treating Menopause Hypertension

Discussion About Diagnosis and Treatment Regularity of Infectious Lung Disease Epidemic and New Explanation of Lianhua Qingwen Formula

Top 10 Academic Progress of Traditional Chinese Medicine in 2023

Evaluation of GRADE Clinical Research Evidence of Chinese Patent Medicine Combined with Western Medicine in Treatment of Hypertension with Dyslipidemia

Related Author

YANG Yufei

TANG Lili

SUN Lingyun

PANG Ying

WANG Zixu

YANG Qiuli

XU Yun

ZHANG Haibo

Related Institution

Xiyuan Hospital，China Academy of Chinese Medical Sciences

Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences

Guangdong Provincial Hospital of Chinese Medicine

National Key Laboratory of Collateral Disease Theory Innovation and Transformation， Hebei Institute of Integrated Chinese and Western Medicine

Shaanxi University of Chinese Medicine

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰